Skip To Main Content

Thyrogen Accessibility Statement

 

1. Commitment

Sanofi is committed to providing digital solutions that are accessible to the widest possible audience, regardless of ability, disability, race, cultural background, gender, or technological requirements.
This accessibility statement applies to www.thyrogen.com

 

2. Conformance status

The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. This website is partially conformant with WCAG 2.2 Level AA, due to the limitations described below.
 

 

3. Known limitations

Despite our best efforts to ensure the accessibility of this website, there may be some limitations. Below is a description of known limitations and potential solutions. Please contact us if you observe an issue not listed below.
 

  • Keyboard focus: When navigating the site by keyboard, the focus state or highlight is challenging to see, including some buttons that are inside of colored containers.
  • Keyboard navigation: Some navigational elements are not accessible through keyboard navigation.
  • Images: Some images may lack descriptive alternative text.
  • Interactive controls: Some interactive areas of the website, including forms, have elements that may be inaccessible by keyboard or by screen reader navigation. If you are unable to complete a form, please contact us for support.
  • Color contrast ratio: Some elements do not meet the minimum thresholds and may be challenging for some people to view and distinguish.
  • Links readability: Some links are identified only with color 

 

4. Feedback and contact

Please contact us if you encounter accessibility barriers on this website. If you are unable to access any content or service, we will provide an accessible alternative or offer the content in another form.

 

5. Preparation of this accessibility statement 

This statement was prepared on February 4, 2026
To evaluate the current level of accessibility, the website was assessed using manual testing, based on WCAG 2.2 Level AA, with Microsoft Edge

Further tests will be carried out by August, 2026
 

6. Formal complaints 

If you are not satisfied with our response to you, you are entitled to escalate a complaint to the national authority.
To file an Americans with Disabilities (ADA) complaint, submit a report with the US Department of Justice, Civil Rights Division, online or by mail. Learn how to file a complaint on the Civil Rights Division website.
 

Important Safety Information and Indication

Thyrogen (thyrotropin alfa) is used to help identify thyroid disease by testing the blood for a hormone called thyroglobulin in the follow up of patients with a certain type of thyroid cancer known as well differentiated thyroid cancer. It is used with or without a radiology test using a form of iodine.

Limitations of Use:

  • The effect of Thyrogen on long term thyroid cancer outcomes has not been determined.
  • When Thyrogen is used to help detect thyroid cancer, there is still a chance all or parts of the cancer could be missed.

Thyrogen is also used to help patients prepare for treatment with a form of iodine, called radioiodine, to remove leftover thyroid tissue in patients who have had surgery to take out the entire thyroid gland for patients with well differentiated thyroid cancer who do not have signs of thyroid cancer which has spread to other parts of the body.

Limitations of Use:

  • In a study of people being prepared for treatment with a form of iodine after thyroid surgery, results were similar between those who received Thyrogen and those who stopped taking their thyroid hormone for up to 5 years after treatment. Researchers do not know if results would be similar over a longer period of time.

Patients should not use Thyrogen with radioiodine if they have a contraindication to the use of radioiodine. Please consult with your doctor for a list of contraindications for radioiodine.

Thyrogen can cause serious side effects, including:

Thyrogen-Induced Hyperthyroidism:

  • There have been reports of events that led to death in patients who have not had surgery to have their thyroid gland removed, and in patients with thyroid cancer cells that have spread to other parts of the body.
  • Patients over 65 years old with large amounts of leftover thyroid tissue after surgery, or with a history of heart disease, should discuss with their physicians the risks and benefits of Thyrogen.
  • Thyrogen can be administered in the hospital for patients at risk for complications from Thyrogen administration.

Stroke:

  • Since Thyrogen was first approved for use, there have been reports of central nervous system problems such as stroke in young women who have a higher chance of having a stroke, and weakness on one side of the body. The relationship between THYROGEN administration and stroke is unknown. Patients should remain hydrated prior to treatment with Thyrogen.

Sudden Rapid Tumor Enlargement:

  •  Leftover thyroid tissue after surgery and cancer cells that have spread to other parts of the body can quickly grow and become painful after Thyrogen administration. Patients with cancer cells near their windpipe, in their central nervous system, or in their lungs may need treatment with a glucocorticoid (a medication to help prevent an increase in the size of the cancer cells before using Thyrogen.)

Risks Associated with Radioiodine Treatment: 

  • If THYROGEN is administered with radioiodine (RAI), the serious side effects for RAI apply to this combination regimen. Please consult with your doctor for a list of contraindications for radioiodine. 

ADVERSE REACTIONS

In clinical studies, the most common side effects reported were nausea and headache.

USE IN SPECIFIC PATIENT POPULATIONS

Pregnant patients: Notify your healthcare provider immediately in the event of a pregnancy. If THYROGEN is administered with radioiodine, the combination regimen should not be used in pregnant women. Thyrogen should be given to a pregnant woman only if the doctor thinks there is a clear need for it.

Breastfeeding patients: If THYROGEN is administered with radioiodine, the combination regimen should not be used in breastfeeding women. It is not known whether Thyrogen can appear in human milk. Breastfeeding women should discuss the benefits and risks of Thyrogen with their physician.

Children: Safety and effectiveness in young patients (under the age of 18) have not been established.

Elderly: Studies do not show a difference in the safety and effectiveness of Thyrogen between adult patients less than 65 years and those over 65 years of age.

Patients with kidney disease: Thyrogen exits the body much slower in dialysis patients and can lead to longer high TSH levels.

 

Click here for full Prescribing Information including Serious Side Effects.

Click here for full Patient Information including Serious Side Effects.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.